

BELGIUM

Recent changes in pharmaceutical policy measures and developments in pharmaceutical expenditure

Major changes in pharmaceutical policy in 2012-2013

Pricing

- **Price changes:**

"1,95% measure" (01/04/2012 & 01/04/2013):

Price cuts on products of choice/all products saving = 1,95% sales year-2

- **Price freezes maintained in 2012-2013**

- **Review reimbursement level of PPI (01/06/2012) & C08/C09A/C09B/N06A (01/05/2013)**

- **Managed-entry agreements:**

2012: BENLYSTA - BRILIQUE - INCIVO - JEVTANA - PRADAXA 110 mg & 150 mg (prevention CVA/SE) - YERVOY - ZYTIGA

2013: XARELTO – ZELBORAF

- **Disconnection generic – reference (after admission)(2012)**

Reimbursement

- **Reference price system changes (methodology)(01/04/2012):**

fully reimbursed pharmaceuticals: reimbursement level is reduced with 41% (instead of 31%)

"exceptions": reimbursement level is reduced but only with half of the percentage

- **New reimbursement category "F" for EPOs (price ≠ reimbursement level)(01/09/2012)**

- **"cheapest pharmaceuticals" rule for INN prescriptions (01/04/2012)**

Other changes

- **Mandatory substitution to "cheapest pharmaceuticals" for antibiotics/antimycotics (01/04/2012)**

Outlook

Reform pricing system for pharmaceuticals dispensed to elderly people in rest and nursing homes (out-patient sector)(end of 2013)

Impact of measures and evaluation

Prescription quota for "cheap" medicines are obtained


Individual feedback prescription profile ("cheap" medicines)

85 % pharmaceuticals are "cheapest" (out-patient)

BELGIUM


Development of pharmaceutical expenditure in the last 5 available years

Out-patient sector



Source: IMS Health, Farmanet

In-patient sector:



Source: IMS Health, Farmanet

Total market: no data available